Liz joined HERC in February 2018, from the Centre for the Advancement of Sustainable Medical Innovation (CASMI) - a policy research group in Oxford’s Radcliffe Department of Medicine. Her work focused on the health economics of cancer drugs, exploring the impact of technology appraisal processes on patient access to drugs, and the value that society places on treating cancer relative to other conditions.
Before joining CASMI, Liz worked as a freelance researcher with clients in pharmaceuticals and education, and as a product development manager in consumer healthcare.
Liz is working with Sarah Wordsworth and colleagues, initially on a series of Discrete Choice Experiments exploring clinician and public attitudes to antibiotics and antimicrobial resistance.
Mind the gap? The platform trial as a working environment
MORRELL L. et al, (2019), Trials, 2019, 297 - 297
Correction to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
Morrell L. et al, (2019), BMC health services research, 19, 198 - 198
Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
Morrell L. et al, (2018), BMC Health Serv Res, 18
The ‘molecularly unstratified’ patient: a focus for moral, psycho-social and societal research
Hordern JWS. et al, (2017), Biomedicine Hub
Cancer as the “perfect storm”? A qualitative study of public attitudes to health conditions
Morrell L. et al, (2017), Health Science Reports